Universal Ibogaine Stock Net Income
| IBOGF Stock | USD 0.01 0.0009 17.65% |
Fundamental analysis of Universal Ibogaine allows traders to better anticipate movements in Universal Ibogaine's stock price by examining its financial health and performance throughout various phases of its business cycle.
Universal |
Universal Ibogaine Company Net Income Analysis
Universal Ibogaine's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Universal Ibogaine Net Income | (10.5 M) |
Most of Universal Ibogaine's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Universal Ibogaine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Universal Ibogaine reported net income of (10.5 Million). This is 103.08% lower than that of the Healthcare sector and 114.98% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.84% higher than that of the company.
Universal Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Universal Ibogaine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Universal Ibogaine could also be used in its relative valuation, which is a method of valuing Universal Ibogaine by comparing valuation metrics of similar companies.Universal Ibogaine is currently under evaluation in net income category among its peers.
Universal Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (4.29) % | |||
| Current Valuation | 4.25 M | |||
| Shares Outstanding | 191.14 M | |||
| Shares Owned By Insiders | 9.51 % | |||
| Price To Book | 1.25 X | |||
| Price To Sales | 3.67 X | |||
| Revenue | 1.07 M | |||
| Gross Profit | 497.15 K | |||
| EBITDA | (10.16 M) | |||
| Net Income | (10.5 M) | |||
| Cash And Equivalents | 1.95 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.74 M | |||
| Debt To Equity | 0.24 % | |||
| Current Ratio | 2.40 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (4.33 M) | |||
| Earnings Per Share | (0.02) X | |||
| Market Capitalization | 2.84 M | |||
| Total Asset | 6.32 M | |||
| Z Score | -2.7 | |||
| Net Asset | 6.32 M |
About Universal Ibogaine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Universal Ibogaine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Universal Ibogaine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Universal Ibogaine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Universal Pink Sheet
Universal Ibogaine financial ratios help investors to determine whether Universal Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Universal with respect to the benefits of owning Universal Ibogaine security.